Detection of low level nilotinib or dasatinib resistant BCR-ABL mutations by mass spectrometry in CML patients who fail Imatinib is highly predivtive of their subsequent clonal expansion when treated with the drug for which their mutation confers resistance
Date
2010
Authors
Parker, W.
Ho, M.
Lawrence, R.
Irwin, D.
Scott, H.
Hughes, T.
Branford, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Conference paper
Citation
Proceedings of 2010 american society of hematology meeting, 2010
Statement of Responsibility
Wendy T Parker, Musei Ho, Rebecca M Lawrence, Darryl L Irwin, Hamish S Scott, Timothy Hughes and Susan Branford
Conference Name
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
Abstract
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright status unknown